In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC Links Pipeline To Loyalty Program Trends, Builds Private Label Lines

This article is powered by The Rose Sheet

Executive Summary

CEO Ken Martindale says research and development linked to firm’s loyalty program, which provides data on the needs of the nearly 15m customers enrolled. “The data-driven insight we gain from our loyalty program are beginning to help us shape our product development and innovation,” he says.

You may also be interested in...



GNC Prioritizes Product Launches, Store Redesigns To Steer Sales Growth

GNC is launching numerous products including an energy drink for millennials and a patented ingredient to improve upper and lower body strength. It also is giving its stores a face lift to implement a "service-driven” concept.

Health, Beauty And Wellness News: Herbalife Q3, NPA On Part 111 Trends, AHPA's Zimmerman Awarded

AHPA's Zimmerman receives AHG's 'Best Contribution' award; NPA notes Part 111 violations common and emerging; saw palmetto BAPP update notes adulteration developments; China results lead Herbalife sales jump; and China deal delay moves GNC Q3 report date.

GNC Prioritizes Boosting Sales Of Its Own Brands For Stronger Mix, Larger Margins

Every 1% increase in GNC brands' sales drives $1m to $3m incremental growth profit for the nutrition, health and wellness manufacturer and retailer, says CFO Tricia Tolivar. The firm targets making its own products a larger part of its brand mix after its brands slipped to 43% of its sales in the first half of 2017.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel